Are you having trouble viewing this email? If so, click here to see it in a web browser. | | | | | | | | | |  | | MARCH 8, 2010 | High Patient Turnover Hampers Personalized Medicine | | The high customer turnover of many U.S. commercial health-care payers limits the potential usefulness of what's known as "personalized medicine" — a tailored approach to treatment based on the molecular analysis of genes, proteins, and metabolites. High turnover makes it less economically attractive for these payers to reimburse younger patients for tests and interventions to treat conditions that tend to occur later in life. The BRCA1 breast-cancer test is a case in point. Europe's single-payer systems, with lower turnover, are less exposed to this challenge. | |  | | Source: The microeconomics of personalized medicine | | Copyright © 2010 McKinsey & Company. All rights reserved. Reprinted by permission. | | | | | | RELATED PRODUCT |  | | Conquering a Culture of Indecision | | Classic Harvard Business Review Article | | The single greatest cause of corporate underperformance is the failure to execute. According to author Ram Charan, such failures usually result from misfires in personal interactions. | | | | | | | | | ADVERTISEMENT | | | |  | | | | | | Follow the Stat: |  |  | | | | | | BEST SELLERS | | | | | | PREVIOUS STATS | | | | | | | | | | | | | | | |  | Copyright © 2010 Harvard Business School Publishing, an affiliate of Harvard Business School. All rights reserved. Harvard Business Publishing | 60 Harvard Way | Boston, MA 02163 Customer Service: 1-800-545-7685 (617-783-7600 outside the U.S. and Canada) | | |